MX2017010323A - Formulaciones farmaceuticas de inhibidor de esterasa c1. - Google Patents

Formulaciones farmaceuticas de inhibidor de esterasa c1.

Info

Publication number
MX2017010323A
MX2017010323A MX2017010323A MX2017010323A MX2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
esterase inhibitor
inh
ameliorated
exhibiting
Prior art date
Application number
MX2017010323A
Other languages
English (en)
Spanish (es)
Inventor
Schaefer Wolfram
Juergen Kanzy Ernst
Metzner Hubert
May Frauke
Pragst Ingo
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of MX2017010323A publication Critical patent/MX2017010323A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017010323A 2015-02-20 2016-02-19 Formulaciones farmaceuticas de inhibidor de esterasa c1. MX2017010323A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15156010 2015-02-20
PCT/EP2016/053559 WO2016131958A1 (en) 2015-02-20 2016-02-19 Pharmaceutical formulations of c1 esterase inhibitor

Publications (1)

Publication Number Publication Date
MX2017010323A true MX2017010323A (es) 2017-12-07

Family

ID=52573617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010323A MX2017010323A (es) 2015-02-20 2016-02-19 Formulaciones farmaceuticas de inhibidor de esterasa c1.

Country Status (13)

Country Link
US (1) US20180036394A1 (OSRAM)
EP (1) EP3258911A1 (OSRAM)
JP (1) JP6516855B2 (OSRAM)
KR (1) KR20170118856A (OSRAM)
CN (1) CN107257683A (OSRAM)
AU (1) AU2016221627A1 (OSRAM)
BR (1) BR112017017685A2 (OSRAM)
CA (1) CA2977090A1 (OSRAM)
IL (1) IL253824A0 (OSRAM)
MX (1) MX2017010323A (OSRAM)
RU (1) RU2017132449A (OSRAM)
SG (1) SG11201706019XA (OSRAM)
WO (1) WO2016131958A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
CN120381522A (zh) * 2025-04-02 2025-07-29 南方医科大学南方医院 一种治疗肝硬化门脉高压的化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2758076B1 (en) * 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
DE202014011208U1 (de) * 2013-03-15 2018-08-23 Shire Viropharma Incorporated C1-INH Zusammensetzungen für die Vorbeugung und Behandlung von Störungen, die mit C1-Esterasehemmer-Defizienz assoziiert sind

Also Published As

Publication number Publication date
RU2017132449A3 (OSRAM) 2019-09-05
JP6516855B2 (ja) 2019-05-22
EP3258911A1 (en) 2017-12-27
KR20170118856A (ko) 2017-10-25
IL253824A0 (en) 2017-09-28
US20180036394A1 (en) 2018-02-08
CA2977090A1 (en) 2016-08-25
JP2018509398A (ja) 2018-04-05
AU2016221627A1 (en) 2017-08-17
RU2017132449A (ru) 2019-03-21
WO2016131958A1 (en) 2016-08-25
BR112017017685A2 (pt) 2018-04-10
CN107257683A (zh) 2017-10-17
SG11201706019XA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MY200356A (en) Kras g12c inhibitors
NZ763551A (en) Compounds useful for inhibiting cdk7
MY199220A (en) Heterocyclic compounds as immunomodulators
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
PH12014502699A1 (en) Pyrimidinyl tyrosine kinase inhibitors
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
SA516380290B1 (ar) نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12014502056A1 (en) 3,5-diaminopyrazole kinase inhibitors
NZ708821A (en) Lfa-1 inhibitor formulations
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2017010323A (es) Formulaciones farmaceuticas de inhibidor de esterasa c1.
PH12017501334A1 (en) 3,5-diaminopyrazole kinase inhibitors
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти